# GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease

> **NCT00228839** · PHASE1 · COMPLETED · sponsor: **Emory University**

## Conditions studied

- Graft vs Host Disease

## Interventions

- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT00228839
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** — (—)
- **Last updated:** 2009-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00228839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00228839, "GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00228839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*